GlaxoSmithKline plc (LON:GSK) has been assigned a GBX 1,834 ($22.35) target price by analysts at Sanford C. Bernstein in a report issued on Wednesday. The brokerage currently has a a “neutral” rating on the stock. Sanford C. Bernstein’s target price suggests a potential upside of 10.02% from the stock’s previous close.

Several other equities research analysts have also issued reports on the stock. Goldman Sachs Group Inc. set a GBX 1,800 ($21.94) price objective on shares of GlaxoSmithKline plc and gave the company a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a GBX 1,667 ($20.32) price objective on shares of GlaxoSmithKline plc in a research note on Wednesday. HSBC reaffirmed a “buy” rating and issued a GBX 1,970 ($24.01) price objective on shares of GlaxoSmithKline plc in a research note on Monday, September 12th. Deutsche Bank AG reaffirmed a “hold” rating on shares of GlaxoSmithKline plc in a research note on Monday, June 27th. Finally, Shore Capital reaffirmed a “hold” rating on shares of GlaxoSmithKline plc in a research note on Wednesday, July 27th. Three research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of GBX 1,680.71 ($20.48).

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

GlaxoSmithKline plc (LON:GSK) traded down 0.33% during midday trading on Wednesday, hitting GBX 1661.50. The company had a trading volume of 2,331,722 shares. The company’s 50 day moving average is GBX 1,651.49 and its 200 day moving average is GBX 1,567.94. The stock’s market cap is GBX 80.77 billion. GlaxoSmithKline plc has a 12-month low of GBX 1,277.25 and a 12-month high of GBX 1,745.56.

The firm also recently disclosed a dividend, which was paid on Thursday, October 13th. Investors of record on Thursday, August 11th were issued a GBX 19 ($0.23) dividend. The ex-dividend date was Thursday, August 11th. This represents a yield of 1.12%.

In other news, insider Slaoui,Moncef bought 28 shares of the business’s stock in a transaction on Friday, August 12th. The shares were bought at an average cost of GBX 2,208 ($26.91) per share, for a total transaction of £618.24 ($753.49). Also, insider Witty,Sir Andrew P sold 10,000 shares of the stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($20.63), for a total transaction of £169,300 ($206,337.60).

About GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.